EZH2 and metastatic neoplasm: In breast cancers, where PRC2 activity is elevated in metastatic disease, high levels of enhancer of zeste 2 polycomb repressive complex 2 (EZH2) are associated with repression of TIMP expression via H3K27me3 silencing (42).